Device-Free Auricular Acupressure Eased Rosacea Severity in a Sham-Controlled Trial
A seed pressed onto the ear may sound modest next to a biologic or laser, but in this randomized clinical trial it produced a measurable shift in rosacea control. Participants receiving device-free auricular acupressure were more likely to reach treatment success at 8 weeks than those assigned to sham stimulation, while serum biomarkers linked to neurogenic inflammation moved in the same direction. The design matters here because the control arm was not inert: it used a seed on a different auricular site with pure somatosensory innervation, allowing a sharper look at whether the therapeutic signal depended on vagal pathways rather than expectation alone.
The trial enrolled 204 patients with rosacea who were already receiving standard first-line treatment, then randomized them equally to active or sham acupressure. Active treatment placed a Vaccaria segetalis seed on the bilateral cavum conchae, an auricular region innervated by the vagal branch. The sham group received a seed on the auricular tubercle superior margin, a site chosen to avoid vagal stimulation. Participants pressed the seed three times daily for 30 seconds, with extra pressing allowed during flare-ups, and the intervention continued for 8 weeks. This was not a passive exposure; it was a repeated, behavior-linked intervention that may have mattered for both physiologic stimulation and adherence.
Clinical Response at Eight Weeks Favored the Active Arm
At the end of treatment, 58 of 102 participants in the active group reached the prespecified primary outcome of Investigator Global Assessment success, defined as a score of 0 or 1. In the sham group, 36 of 102 reached that threshold. The relative risk was 1.61, with a 95% CI of 1.18 to 2.20 and a P value of .003. The number needed to treat was 5.
That absolute difference is clinically meaningful in a condition where patients often judge success by whether flushing, papules, and background erythema stop dictating daily routines. A number needed to treat of 5 means the effect was not confined to biomarker theory or marginal score shifts. It translated into a tangible bedside difference for a subset of patients already on standard therapy.
The cohort was relatively young, with a mean age of 32.51 years in the active group and 30.82 years in the sham group. Women made up 84.3% of each arm. Those demographics do not explain the treatment effect by themselves, but they do frame the population in which the intervention was tested: adults with rosacea early enough in life to make self-administered, low-burden treatment especially attractive if efficacy holds up elsewhere.
Biomarker Shifts Pointed to Neuroimmunomodulation
Serum LL-37, CGRP, TNF-α, and IL-6 fell more in the active group than in the sham group. The biological logic is straightforward. Rosacea is not only a vascular disorder; it is also driven by dysregulated innate immunity, neuropeptide signaling, and inflammatory amplification within the skin. LL-37 has long been tied to rosacea pathobiology, while CGRP can promote vasodilation and neurogenic inflammation. TNF-α and IL-6 represent broader inflammatory activity that can sustain cutaneous reactivity once the flare cycle is underway.
A therapy that lowers this biomarker cluster is doing more than masking redness. It is acting along pathways that fit the disease mechanism itself, which strengthens the plausibility of a neuromodulatory effect rather than a nonspecific comfort effect. The trial therefore linked symptom improvement to a measurable biologic shift, a useful combination when evaluating a modality that has often been discussed in broad mechanistic terms without sham-controlled serum evidence.
Early Vascular Imaging Changed Before the Full Clinical End Point
Multispectral imaging at week 4 showed an immediate vascular improvement rate of 59.3% in the active group versus 7.4% in the sham group. Even without every imaging detail in view, the direction of effect is hard to ignore. Vascular reactivity sits at the center of rosacea flares, especially the sudden flushing that patients identify before papules fully declare themselves. If auricular stimulation dampens that response early, it offers a plausible bridge between neurogenic input and visible skin improvement by week 8.
The imaging result also helps separate mechanism from delayed symptom drift. A vascular signal appearing by week 4 suggests the intervention may alter cutaneous reactivity before the full clinical endpoint is reached. For patients, that matters because rosacea treatment often fails when the early inflammatory and flushing pattern stays unchanged long enough to erode confidence in the regimen.
A Device-Free Approach Could Lower the Barrier to Use
Specialized equipment often limits the reach of auricular vagus nerve stimulation, even when early studies suggest benefit. This trial sidestepped that barrier by using a simple seed-based method that patients can apply themselves. The practical value lies not only in cost and portability, but in reproducibility across outpatient settings where access to devices, training, and repeated supervised visits can be inconsistent.
Still, simplicity does not erase the need for caution. The trial was single-center, and the population received concurrent first-line therapy, so the independent contribution of acupressure has to be read in that context. The intervention was assessor-masked and sham-controlled, which strengthens internal validity, yet the broader question is whether these results will hold in other skin types, other care settings, and longer treatment windows. The trial also stops at short-term outcomes; relapse, durability, and patient-reported burden are not established here.
What the Trial Establishes and What It Does Not
The cleanest conclusion is that device-free auricular acupressure improved short-term rosacea outcomes more than sham stimulation, with parallel reductions in inflammatory and neuropeptide markers and a striking early vascular signal. The result supports the idea that auricular stimulation can influence rosacea through neuroimmunomodulatory pathways, not merely through nonspecific pressure or placebo response.
The remaining clinical questions are narrower. Whether the benefit persists after the 8-week course, whether patients can maintain the routine over months, and whether the effect size remains stable outside a single tertiary center are not answered here. Nor does the trial tell clinicians which rosacea phenotypes respond best, or whether biomarker changes can eventually guide patient selection. For now, the study offers a credible biologic and clinical signal, but one that still needs longer follow-up and multicenter confirmation before it can be treated as routine care.